Portal de Periódicos da CAPES

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition

2021; BMJ; Volume: 9; Issue: 1 Linguagem: Inglês

10.1136/jitc-2020-001931

2051-1426

Aljosja Rogiers, Inês Pires da Silva, Chiara Tentori, Carlo Tondini, Joseph M. Grimes, Megan H. Trager, Sharon H. Nahm, Leyre Zubiri, Michael P. Manos, Peter J. Bowling, Arielle Elkrief, Neha Papneja, Maria Grazia Vitale, April A. N. Rose, Jessica S.W. Borgers, Séverine Le Roy, Joanna Mangana, Thiago Pimentel Muniz, Tim Cooksley, Jéremy Lupu, A Vaisman, Samuel D. Saibil, Marcus O. Butler, Alexander M. Menzies, Matteo S. Carlino, Michael Erdmann, Carola Berking, Lisa Zimmer, Dirk Schadendorf, Laura Pala, Paola Queirolo, Christian Posch, Axel Hauschild, Reinhard Dummer, John B.A.G. Haanen, Christian U. Blank, Caroline Robert, Ryan J. Sullivan, Paolo A. Ascierto, Wilson H. Miller, F. Stephen Hodi, Karijn P.M. Suijkerbuijk, Kerry L. Reynolds, Osama E. Rahma, Paul Lorigan, Richard D. Carvajal, Serigne Lo, Mario Mandalà, Georgina V. Long,

Cancer survivorship and care

Patients with cancer who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more likely to develop severe illness and die compared with those without cancer. The impact of immune checkpoint inhibition (ICI) on the severity of COVID-19 illness is unknown. The aim of this study was to investigate whether ICI confers an additional risk for severe COVID-19 in patients with cancer.